Catalent is applying ABEC’s technology to expand its plasmid DNA manufacturing capabilities
ABEC, a leading global provider of integrated solutions and services for biopharmaceutical manufacturing, has supplied two 50 L CSR single-use fermenters to Catalent Cell & Gene Therapy. The custom systems were delivered on an accelerated schedule for specific process requirements and are now in operation at Catalent’s Plasmid production facility in Rockville, Maryland.
Catalent is applying ABEC’s technology to expand its plasmid DNA manufacturing capabilities. The fermenters were designed to provide process flexibility for plasmid products and to integrate into existing space in Catalent’s Rockville facility.
ABEC’s CSR fermentation technology delivers process performance comparable to that of stainless-steel systems, the company claims, ensuring highly productive and scalable fermentation processes. It’s also supplying CSR single-use disposable containers (DCs) from its two in-house ISO-7 cleanroom manufacturing facilities in Bethlehem, Pa. and Fermoy, County Cork, Ireland. These facilities, as well as ABEC’s qualification of multiple single-use instrument and component suppliers, are designed to ensure a robust supply chain and short DC lead times.
Dr Thomas VanCott, Catalent’s Global Head of Product Development, Cell & Gene Therapy said: “The ABEC CSR fermenters are optimized for our demanding plasmid fermentation processes, and ABEC’s commitment and credibility are essential to support our rapid growth.”
“We are pleased to support Catalent with our industry-leading single-use microbial fermentation technology,” said Scott Pickering, ABEC CEO and Chairman. “Our complete in-house equipment and disposables supply capabilities were also crucial for success in this effort.”